OpenAI launches GPT‑Rosalind

Drug discovery starts with a bottleneck: scientists spend years sorting through genes, proteins and papers before a single medicine reaches human testing. OpenAI said on April 16 it is releasing GPT‑Rosalind, a model built for that early research work. (openai.com) OpenAI said GPT‑Rosalind is designed for biology, drug discovery and translational medicine, with stronger performance on chemistry, protein engineering and genomics tasks than its general models. The company is offering it first in a research preview through a “trusted-access” program for eligible institutions. (openai.com, openai.com) Genomics is the study of DNA, the instruction code inside cells, and protein engineering is the work of changing the molecules that do much of a cell’s labor. OpenAI said Rosalind is meant to help researchers connect those pieces across databases, lab results and scientific literature. (openai.com, openai.com) OpenAI framed the pitch around time and cost: its research post says a new drug in the United States typically takes about 10 to 15 years to move from target discovery to regulatory approval. The company said better work at the front end can improve target selection, biological hypotheses and experiment design later on. (openai.com) The release lands as OpenAI is putting more weight on paying workplace customers than on broad consumer experiments. Chief financial officer Sarah Friar told The Associated Press this week that OpenAI will soon introduce a model for “high-value professional work” as it competes with Anthropic for business users. (pbs.org, usnews.com) That same Associated Press report said OpenAI has been shedding some consumer offerings while steering resources toward business products and profitability. Reuters separately reported on April 14 that investors were questioning OpenAI’s strategy after the company redrew its product roadmap twice in six months in response to pressure first from Google and then from Anthropic. (abcnews.com, money.usnews.com) The science push also puts OpenAI into a field already crowded with specialist tools. Bloomberg reported that the company is joining other tech groups trying to prove artificial intelligence can speed drug discovery, while OpenAI’s own materials position Rosalind as a reasoning system for hypothesis generation and workflow support rather than a single-purpose structure predictor. (bloomberg.com, openai.com) OpenAI has not opened Rosalind as a general public chatbot. For now, it is treating the model as restricted research infrastructure, a sign that its next growth pitch is aimed less at casual prompts and more at labs and employers willing to pay for specialized work. (openai.com, fastcompany.com)